Figure 6 from FLT3/CD99 Bispecific Antibody–Based Nanoparticles for Acute Myeloid Leukemia

Midostaurin-resistant MV4-11 cells show sensitivity to CD99/FLT3 antibody-based nanoparticles. MV4-11 cells were selected with resistance to increasing concentrations of midostaurin during several months of culture and evaluated by flow cytometry. A–C, Apoptosis experiments illustrate how the live-cell (Q4) percentage for midostaurin-resistant MV4-11 cells is decreased when compared to naïve cells, eluding at their maintained and increased sensitivity to the different treatment formulations. D, The antibody-based nanoparticles were evaluated against both naïve and resistant cell lines, which show that the nanoparticles maintain their effect in resistant MV4-11 cells, illustrated by the reduction of cell viability. E and F, Engraftment of 10⁶ MV4-11-R cells in NSG mice following the same treatment regiments as previous MV4-11 in vivo experiments show a significant decrease in the percentage of huCD45 cells between A192 and the Co-Assembled construct. Additionally, naïve MV4-11 cells were engrafted as a control to illustrate the effect of midostaurin.